Combination of acupuncture and Chinese herbal formula for elderly adults with mild cognitive impairment: Protocol for a randomized controlled trial
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractBackground: Mild cognitive impairment (MCI) is known as a transitional status between normal cognitive function and Alzheimer's disease (AD). Acupuncture and Chinese herbal medicines (CHMs) are considered to be beneficial to patients with cognitive impairment. However, it is still unknown whether the combination of the two therapies could optimize the therapeutic effect for MCI. This trial is aimed to evaluate the therapeutic effects of acupuncture and the herbal formula Yishen Granule (YSG) for elderly patients with MCI. Methods/design: This is a multi-sited, patient-blinded, randomized controlled trial (RCT). Two hundred and forty eligible patients will be randomly divided into four groups: A. acupuncture with YSG, B. acupuncture with placebo herbal medicine, C. sham acupuncture with YSG or D. sham acupuncture with placebo herbal medicine. Acupuncture treatment will be given twice a week for 8 weeks and then once a week for 4 weeks. The herbal treatment patients will be given granules daily for 12 weeks, 8 weeks of standard-dose followed by 4 weeks of mid-dose. The primary outcome is scored by the Montreal Cognitive Assessment (MoCA). The secondary outcomes will be scored by the Mini-Mental State Examination (MMSE) and event-related potential (ERP). All the assessments will be conducted at baseline, and at the eighth and 12th week after intervention starts. The follow-up assessments will be performed with the MoCA in the 12th, 24th, and 36th weeks after intervention ends. Intention-to-treat (ITT) analysis will be used in this RCT. Discussion: This RCT will provide us information on the effect of treating MCI patients with only acupuncture, herbal formula as well as the combination of both. The additive effect or synergistic effect of acupuncture and Chinese herbal formula will then be analyzed. Trial registration: This trial is registered with ChiCTR-INR-17011569 on 5 June 2017, and has been approved by the Ethics Committee of Shanghai Municipal Hospital of Traditional Chinese Medicine (2017SHL-KY-05). © 2019 The Author(s).
SponsorsThis RCT is funded by the Shanghai Municipal Commission of Health and Family Planning (Grant No. 2015ZB0504).
Chinese herbal formula
Mild cognitive impairment (MCI)
Randomized controlled trial (RCT)
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85061363147&doi=10.1186%2fs13063-019-3212-z&partnerID=40&md5=38bae6336f50b9acde6accac55c611f3; http://hdl.handle.net/10713/8600
- Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
- Authors: Steiner GZ, Bensoussan A, Liu J, Hohenberg MI, Chang DH
- Issue date: 2018 Sep 25
- Neurocircuitry of acupuncture effect on cognitive improvement in patients with mild cognitive impairment using magnetic resonance imaging: a study protocol for a randomized controlled trial.
- Authors: Suh HW, Kim J, Kwon O, Cho SH, Kim JW, Kwak HY, Kim Y, Lee KM, Chung SY, Lee JH
- Issue date: 2019 May 30
- Effects of different acupuncture treatment methods on mild cognitive impairment: a study protocol for a randomized controlled trial.
- Authors: Kim JH, Cho MR, Park GC, Lee JS
- Issue date: 2019 Sep 4
- Effectiveness of Yi-Zhi-An-Shen granules on cognition and sleep quality in older adults with amnestic mild cognitive impairment: protocol for a randomized, double-blind, placebo-controlled trial.
- Authors: Yue S, He T, Li B, Qu Y, Peng H, Chen J, Lei M, Chen C, Wu W
- Issue date: 2019 Aug 20
- The effectiveness and safety of Kami Guibi-tang for mild cognitive impairment: study protocol of a pilot, randomized, placebo-controlled, double-blind trial.
- Authors: Shin HY, Kim JH, Jahng GH, Jung WS, Park SU, Ko CN, Park JM
- Issue date: 2019 Jul 22